Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Chemotherapy Cycles and Ovarian Clear Cell Carcinoma

Gynecol Oncol; ePub 2016 Dec 12; Prendergast, et al

Survival rates for women with stage I-II ovarian clear cell carcinoma (OCCC) were similar after 3 or 6 cycles of platinum-based chemotherapy, a recent study found, and patients with early stage I and II OCCC may be candidates for a 3-cycle treatment approach. The cohort included 210 patients (median age 53 years) with stage I-II OCCC treated at 5 institutions from January 1994 through December 2011 and identified and divided into 2 groups: those who received 3 vs 6 cycles of adjuvant chemotherapy. Researchers found:

  • All patients received adjuvant chemotherapy with 90% receiving carboplatin and paclitaxel.
  • 38 (18.1%) patients received 3 cycles, and 172 (81.9%) patients received 6 cycles of adjuvant treatment.
  • Recurrence rate was comparable between groups (18.4% vs 27.3% for 3 vs 6 cycles).
  • No impact of 3 vs 6 cycles of chemotherapy on progression-free survival was observed.
  • No benefit was found in more chemotherapy in stratified analysis by stage nor on multivariate analysis adjusting for the impact of stage.

Citation:

Prendergast EN, Holzapfel M, Mueller JJ, et al. Three versus six cycles of adjuvant platinum-based chemotherapy in early stage clear cell ovarian carcinoma – A multi-institutional cohort. [Published online ahead of print December 12, 2016]. Gynecol Oncol. doi:10.1016/j.ygyno.2016.12.004.